Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 4/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449630 | 0.82 | SYK (0.54) | CYP19A1SYKKMT2AAURKBINCENP | |
| SCHEMBL6450412 | 0.81 | GUSB (0.43) | CYP19A1KMT2AMEN1ALOX15KDM4E | |
| SCHEMBL6449917 | 0.78 | MAPT (0.50) | CYP19A1KMT2AMEN1ALOX15L3MBTL1 | |
| SCHEMBL6448824 | 0.76 | GRIN1 (0.46) | CYP19A1SYKPLA2G2AGRIN1GRIN2B | |
| SCHEMBL6454652 | 0.74 | BRS3 (0.40) | CYP19A1KMT2AMEN1ALOX15KDM4E | |
| SCHEMBL5216458 | 0.72 | KDM4E (0.47) | KMT2AMEN1ALOX15L3MBTL1KDM4E | |
| SCHEMBL29167678 | 0.71 | SYK (0.48) | CYP19A1SYKKMT2AMEN1ALOX15 | |
| SCHEMBL6454162 | 0.71 | CYP19A1 (0.46) | CYP19A1KMT2AMEN1ALOX15L3MBTL1 | |
| SCHEMBL6448695 | 0.71 | MAPT (0.50) | CYP19A1SYKKMT2AMEN1ALOX15 | |
| SCHEMBL17239424 | 0.70 | ALDH1A1 (0.49) | KMT2AMEN1L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | CYP19A1 523/4885SYK 4094/4885PLA2G2A 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.